Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-03-05

Clinical Trial Update: Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial to evaluate triheptanoin in patients with Medium-chain Acyl-CoA Dehydrogenase Deficiency is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Triheptanoin (triheptanoin)

Snippet

Sponsor: Jerry Vockley, MD, PhD | Conditions: Medium-chain Acyl-CoA Dehydrogenase Deficiency | Phase 2 | Status: RECRUITING